Literature DB >> 9669467

Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients.

K P Wandinger1, K Wessel, P Trillenberg, N Heindl, H Kirchner.   

Abstract

OBJECTIVES: To investigate the in vivo effect of corticosteroid pulse therapy on immunocompetent cells in 18 patients given methylprednisolone to treat an acute episode of MS.
MATERIAL AND METHODS: Blood was sampled before and after 3 days of methylprednisolone administration at doses of 1 g/day. Lymphocyte subtyping was performed and whole blood cell cultures were used to measure the cytokine producing capacity for interleukin-1 (IL-1), interleukin-2 (IL-2), interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha) and interferon-alpha (IFN-alpha). In addition, serum levels of the immunoglobulin classes IgG, IgA and IgM were determined.
RESULTS: Before treatment, production of IL-1 was significantly increased in MS patients as compared to healthy controls. After therapy, production of all cytokines was significantly decreased, whereas there were significant increases in the numbers of monocytes, neutrophils and T and B lymphocytes. Treatment had no effect on serum immunoglobulin levels.
CONCLUSION: An important mechanism for the antiinflammatory effect of corticosteroids in MS results from a suppression of the activation of the peripheral immune compartment through inhibition of cytokine production and lymphocyte endothelial adhesiveness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669467     DOI: 10.1111/j.1600-0404.1998.tb05966.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  Apoptosis signals in atopy and asthma measured with cDNA arrays.

Authors:  M H Brutsche; I C Brutsche; P Wood; A Brass; N Morrison; M Rattay; N Mogulkoc; N Simler; M Craven; A Custovic; J J Egan; A Woodcock
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

2.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.

Authors:  Xuan Feng; Nicholas P Reder; Mounica Yanamandala; Addie Hill; Beverly S Franek; Timothy B Niewold; Anthony T Reder; Adil Javed
Journal:  J Neurol Sci       Date:  2011-10-27       Impact factor: 3.181

3.  Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

Authors:  A Csiszár; G Nagy; P Gergely; T Pozsonyi; E Pócsik
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 4.  Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects.

Authors:  Anjali Shah; Eric Eggenberger; Robert Zivadinov; Olaf Stüve; Elliot M Frohman
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

5.  The role of chicken IL-1beta, IL-6 and TNF-alpha in the occurrence of amyloid arthropathy.

Authors:  Alper Sevimli; Deniz Misirlioğlu; Artay Yağci; Aziz Bülbül; Arzu Yilmaztepe; Korhan Altunbas
Journal:  Vet Res Commun       Date:  2008-07-09       Impact factor: 2.459

6.  A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment.

Authors:  Stephen L Walker; Peter G Nicholls; Sushmita Dhakal; Rachel A Hawksworth; Murdo Macdonald; Kishori Mahat; Shudan Ruchal; Sushma Hamal; Deanna A Hagge; Kapil D Neupane; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2011-04-12

7.  Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone.

Authors:  Amy Perrin Ross; Aliza Ben-Zacharia; Colleen Harris; Jennifer Smrtka
Journal:  Front Neurol       Date:  2013-03-08       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.